Ca 125 is used for
**Core Concept**
The CA 125 tumor marker is a glycoprotein antigen associated with epithelial ovarian cancer, primarily used for monitoring disease progression and response to treatment in patients with ovarian cancer. Elevated levels of CA 125 can also be found in other conditions, such as endometriosis, pelvic inflammatory disease, and benign ovarian cysts.
**Why the Correct Answer is Right**
CA 125 is a useful marker for monitoring patients with ovarian cancer, particularly those with advanced disease. The level of CA 125 can correlate with tumor burden and response to treatment, allowing clinicians to adjust therapy accordingly. However, it is essential to note that CA 125 can also be elevated in non-malignant conditions, which may lead to false positives.
**Why Each Wrong Option is Incorrect**
**Option A:** CA 125 is used for screening asymptomatic women for ovarian cancer. This is incorrect because CA 125 is not sensitive or specific enough for screening purposes, and other methods such as transvaginal ultrasound (TVUS) and pelvic exam are preferred for initial evaluation.
**Option B:** CA 125 is used for diagnosing ovarian cancer. This is incorrect because while CA 125 can be elevated in ovarian cancer, it is not a reliable marker for diagnosis, and imaging studies and tissue biopsy are essential for definitive diagnosis.
**Option C:** CA 125 is used for monitoring prostate cancer. This is incorrect because CA 125 is not associated with prostate cancer; instead, prostate-specific antigen (PSA) is the primary tumor marker used for monitoring prostate cancer.
**Clinical Pearl / High-Yield Fact**
When interpreting CA 125 levels, it is essential to consider the patient's clinical context, as false positives can occur due to various non-malignant conditions. A rising trend in CA 125 levels over time, rather than an isolated value, is more indicative of disease progression or recurrence.
**Correct Answer: B. CA 125 is used for monitoring disease progression and response to treatment in patients with ovarian cancer.**